The objective of the current study is to investigate the efficacy, safety and tolerability
of linagliptin (5 mg / once daily) compared to placebo given over 12 weeks in drug naive or
previously treated type 2 diabetic patients with moderate to severe renal impairment and
insufficient glycaemic control. In addition safety in this patient population with longer
term (40 week) treatment in comparison to sulfonylurea drug (glimepiride).
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
1218.64.35804 Boehringer Ingelheim Investigational Site, Kokkola, Finland
1218.64.35803 Boehringer Ingelheim Investigational Site, Oulu, Finland
1218.64.35801 Boehringer Ingelheim Investigational Site, Turku, Finland
1218.64.97204 Boehringer Ingelheim Investigational Site, Ashkelon, Israel
1218.64.97207 Boehringer Ingelheim Investigational Site, Givatayim, Israel
1218.64.97203 Boehringer Ingelheim Investigational Site, Haifa, Israel
1218.64.97201 Boehringer Ingelheim Investigational Site, Jerusalem, Israel
1218.64.97202 Boehringer Ingelheim Investigational Site, Nahariya, Israel
1218.64.97206 Boehringer Ingelheim Investigational Site, Tel Aviv, Israel
1218.64.81005 Boehringer Ingelheim Investigational Site, Asahi, Chiba, Japan
1218.64.81006 Boehringer Ingelheim Investigational Site, Isesaki, Gunma, Japan
1218.64.81001 Boehringer Ingelheim Investigational Site, Meguro-ku, Tokyo, Japan
1218.64.81008 Boehringer Ingelheim Investigational Site, Nagoya, Aichi, Japan
1218.64.81007 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan
1218.64.81002 Boehringer Ingelheim Investigational Site, Shinjyuku-ku,Tokyo, Japan
1218.64.81004 Boehringer Ingelheim Investigational Site, Suita, Osaka, Japan
1218.64.81003 Boehringer Ingelheim Investigational Site, Suwa, Nagano, Japan
1218.64.64001 Boehringer Ingelheim Investigational Site, Otahuhu Auckland, New Zealand
1218.64.42102 Boehringer Ingelheim Investigational Site, Bratislava, Slovakia
1218.64.42107 Boehringer Ingelheim Investigational Site, Kosice, Slovakia
1218.64.42109 Boehringer Ingelheim Investigational Site, Nitra, Slovakia
1218.64.42108 Boehringer Ingelheim Investigational Site, Trencin, Slovakia
1218.64.46003 Boehringer Ingelheim Investigational Site, Helsingborg, Sweden
1218.64.46002 Boehringer Ingelheim Investigational Site, Härnösand, Sweden
1218.64.10007 Boehringer Ingelheim Investigational Site, Chula Vista, California, United States
1218.64.10018 Boehringer Ingelheim Investigational Site, Pembroke Pines, Florida, United States
1218.64.10016 Boehringer Ingelheim Investigational Site, Decatur, Georgia, United States
1218.64.10015 Boehringer Ingelheim Investigational Site, Boise, Idaho, United States
1218.64.10002 Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States
1218.64.10004 Boehringer Ingelheim Investigational Site, Flint, Michigan, United States
1218.64.10006 Boehringer Ingelheim Investigational Site, Kansas City, Missouri, United States
1218.64.61005 Boehringer Ingelheim Investigational Site, Gosford, New South Wales, Australia
1218.64.61001 Boehringer Ingelheim Investigational Site, Liverpool, New South Wales, Australia
1218.64.61002 Boehringer Ingelheim Investigational Site, St Leonards, New South Wales, Australia
1218.64.10003 Boehringer Ingelheim Investigational Site, Bronx, New York, United States
1218.64.20008 Boehringer Ingelheim Investigational Site, Corunna, Ontario, Canada
1218.64.20005 Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada
1218.64.20007 Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada
1218.64.20002 Boehringer Ingelheim Investigational Site, Sarnia, Ontario, Canada
1218.64.20009 Boehringer Ingelheim Investigational Site, Stayner, Ontario, Canada
1218.64.20004 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada
1218.64.10013 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States
1218.64.10020 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States
1218.64.10008 Boehringer Ingelheim Investigational Site, Pittsburgh, Pennsylvania, United States
1218.64.20003 Boehringer Ingelheim Investigational Site, Point Claire, Quebec, Canada
1218.64.61003 Boehringer Ingelheim Investigational Site, Adelaide, South Australia, Australia
1218.64.10009 Boehringer Ingelheim Investigational Site, Arlington, Texas, United States
1218.64.10005 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States
1218.64.10011 Boehringer Ingelheim Investigational Site, Houston, Texas, United States
1218.64.10014 Boehringer Ingelheim Investigational Site, Houston, Texas, United States
1218.64.61004 Boehringer Ingelheim Investigational Site, Reservoir, Victoria, Australia
1218.64.10010 Boehringer Ingelheim Investigational Site, Tacoma, Washington, United States